Sources
TipRanks
Eli Lilly $LLY is advancing pediatric diabetes care with a new study on LY3209590, an experimental drug for Type 2 Diabetes in children. This research could boost investor confidence by expanding diabetes treatments into pediatric care.
- TipRanks
Eli Lilly $LLY updates on its Phase 2 study for chronic pain treatments, testing multiple interventions. Positive results could boost investor confidence amid intense competition in the pain treatment market. Study completion expected by August 2025.
- TipRanks
Eli Lilly $LLY is advancing its PIONEER-PEDS1 study, testing lasmiditan for pediatric migraine relief. Success could expand their market in migraine treatment, potentially boosting stock performance. Study ongoing with recruitment active.
